Form 4: Mirum Pharmaceuticals Executive Granted Stock Options and Restricted Stock Units

Mirum Pharmaceuticals' SVP, Global Controller, Jolanda Howe, received stock options and restricted stock units as part of her compensation package.

Summary

• Jolanda Howe, SVP, Global Controller at Mirum Pharmaceuticals, was granted stock options for 18,500 shares at an exercise price of $47.98 on January 21, 2025.
• These options vest over a period of 4 years, with 1/4 vesting one year after the grant date and the remainder vesting monthly over the following 36 months.
• Howe also received 4,625 restricted stock units (RSUs) which vest in three equal annual installments starting January 21, 2026.
• Additionally, 7,973 performance-based restricted stock units (PSUs) vested on January 21, 2025, with 2/3 vesting on March 15, 2025 and the remaining 1/3 vesting on March 15, 2026.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.

Positives

• The granting of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedules for the options and RSUs encourage long-term commitment from the executive.
• The performance-based restricted stock units (PSUs) reward the executive for achieving specific performance goals.

Industry Context

This type of equity-based compensation is common practice in the pharmaceutical industry to attract and retain key executives.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in the biotech and pharmaceutical industries.
• Vesting schedules are typical, designed to incentivize long-term performance and retention.
• The specific terms of the grants, such as the vesting period and performance criteria, are generally aligned with industry norms for companies of similar size and stage of development.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align executive interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, performance stock units, executive compensation, vesting, Mirum Pharmaceuticals, MIRM